STEPP for the EGFR inhibitor-induced rash--definitely a step in the right direction
- PMID: 20437117
- PMCID: PMC9651017
- DOI: 10.1007/s11912-010-0102-7
STEPP for the EGFR inhibitor-induced rash--definitely a step in the right direction
Conflict of interest statement
Comment on
-
Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.J Clin Oncol. 2010 Mar 10;28(8):1351-7. doi: 10.1200/JCO.2008.21.7828. Epub 2010 Feb 8. J Clin Oncol. 2010. PMID: 20142600 Clinical Trial.
References
-
- Solomon BM, Jatoi A: Rash from EGFR inhibitors: opportunities and challenges for palliation. Curr Oncol Rep 2008, 10:304–308. - PubMed
-
- Wagner LI, Lacouture ME: Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Oncology 2007, 21:34–36. - PubMed
-
- Scope A, Agero AL, Dusza SW, et al. : Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007, 25:5390–5396. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
